At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.
More Than Just a Beanie
Worn by celebrities like Frank Ocean and Timothée Chalamet, the Arc’teryx toque isn’t only being used to keep heads warm.
Best Outdoor Clothing Brands Made in the USA
Discover the best outdoor clothing brands made in the USA and invest in reliability while supporting local jobs and ethical ...
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Tired of ‘Quiet Luxury’? These 1980s and ‘90s Power Brands Are Back to Re-energize Womenswear
You’d be forgiven for thinking that power-dressing labels like St. John Knits and Escada went out of business. Instead, ...
Saitex Redefines ‘Fast Fashion’ with Collection Benefiting LA Wildfire Relief
Forever L.A. is the first product of a new eponymous purpose-driven platform the manufacturer is launching this year. Saitex ...
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...